Increased PD-L1 Expression in HER2-Positive Breast Cancer without Pathologic Complete Response to Neoadjuvant Therapy

被引：0
|
作者：
Yang, Fei [1 ]
Song, Juhee [1 ]
Mino, Barbara [1 ]
Parra, Edwin R. [1 ]
Sahin, Aysegul [1 ]
Wistuba, Ignacio [1 ]
Litton, Jennifer [1 ]
Mittendorf, Elizabeth [1 ]
Wu, Yun
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
MODERN PATHOLOGY | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
321
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [21] Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy’’
    Takeo Fujii
    Naoto T Ueno
    British Journal of Cancer, 2017, 116 : e11 - e11
  • [22] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Melissa Krystel-Whittemore
    Jin Xu
    Edi Brogi
    Katia Ventura
    Sujata Patil
    Dara S. Ross
    Chau Dang
    Mark Robson
    Larry Norton
    Monica Morrow
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2019, 177 : 61 - 66
  • [23] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Krystel-Whittemore, Melissa
    Xu, Jin
    Brogi, Edi
    Ventura, Katia
    Patil, Sujata
    Ross, Dara S.
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 61 - 66
  • [24] Microsatellite Instability and PD-1/PD-L1 Expression in HER2-Positive Breast Carcinoma
    Ubago, Julianne M.
    Larson, Alexandra
    Rosen, Lauren
    Novo, Jorge
    Pincus, Jennifer
    Blanco, Luis
    Siziopikou, K. P.
    LABORATORY INVESTIGATION, 2018, 98 : 111 - 111
  • [25] Microsatellite Instability and PD-1/PD-L1 Expression in HER2-Positive Breast Carcinoma
    Ubago, Julianne M.
    Larson, Alexandra
    Rosen, Lauren
    Novo, Jorge
    Pincus, Jennifer
    Blanco, Luis
    Siziopikou, K. P.
    MODERN PATHOLOGY, 2018, 31 : 111 - 111
  • [26] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [27] High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy.
    Zelnak, A. B.
    Leyland-Jones, B.
    Gabram-Mendola, S.
    Styblo, T. M.
    Rizzo, M.
    Wood, W. C.
    Srinivasiah, J.
    Jonas, W. S.
    Schnell, F. M.
    O'Regan, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
    Buzatto, I. P. C.
    Ribeiro-Silva, A.
    Andrade, J. M.
    Carrara, H. H. A.
    Silveira, W. A.
    Tiezzi, D. G.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2017, 50 (02)
  • [29] Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer
    Chen, Yang
    Jia, Keren
    Chong, Xiaoyi
    Xie, Yi
    Jiang, Lei
    Peng, Haoxin
    Liu, Dan
    Yuan, Jiajia
    Li, Yanyan
    Feng, Xujiao
    Sun, Yu
    Li, Jian
    Zhang, Xiaotian
    Shen, Lin
    MOLECULAR CANCER, 2024, 23 (01)
  • [30] Neoadjuvant trastuzumab in HER2-positive breast cancer, is pathological complete response enough?
    Ruvalcaba-Limon, Eva
    Pozo-Romero, Mariela
    Bautista-Pina, Veronica
    Tenorio-Torres, Alberto
    Morales-Vazquez, Flavia
    Rodriguez-Cuevas, Sergio
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 342 - 344
12345